U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H10I4NO4.Na
Molecular Weight 798.8518
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOTHYROXINE SODIUM ANHYDROUS

SMILES

[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O

InChI

InChIKey=YDTFRJLNMPSCFM-YDALLXLXSA-M
InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m0./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H10I4NO4
Molecular Weight 775.8621
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/levothyroxine.html

Levothyroxine (T4) is a synthetically prepared levo isomer of thyroxine, the major hormone secreted from the thyroid gland. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine (T3) which exerts a broad spectrum of stimulatory effects on cell metabolism. Thyroid hormone increases the metabolic rate of cells of all tissues in the body. In the fetus and newborn, thyroid hormone is important for the growth and development of all tissues including bones and the brain. In adults, thyroid hormone helps to maintain brain function, food metabolism, and body temperature, among other effects. The symptoms of thyroid deficiency relieved by levothyroxine include slow speech, lack of energy, weight gain, hair loss, dry thick skin and unusual sensitivity to cold. Levothyroxine acts like the endogenous thyroid hormone thyroxine (T4, a tetra-iodinated tyrosine derivative). In the liver and kidney, T4 is converted to T3, the active metabolite. In order to increase solubility, the thyroid hormones attach to thyroid hormone binding proteins, thyroxin-binding globulin, and thyroxin-binding prealbumin (transthyretin). Transport and binding to thyroid hormone receptors in the cytoplasm and nucleus then takes place. Thus by acting as a replacement for natural thyroxine, symptoms of thyroxine deficiency are relieved. Levothyroxine is used for use alone or in combination with antithyroid agents to treat hypothyroidism, goiter, chronic lymphocytic thyroiditis, myxedema coma, and stupor.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.136 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Synthroid

Approved Use

Levothyroxine tablets are used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer.

Launch Date

2002
Primary
Synthroid

Approved Use

Levothyroxine tablets are used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer.

Launch Date

2002
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
76.64 ng/mL
600 μg single, oral
dose: 600 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOTHYROXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1764.14 ng × h/mL
600 μg single, oral
dose: 600 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOTHYROXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.2 day
unknown, unknown
LEVOTHYROXINE serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7.5 h
unknown, unknown
LEVOTHYROXINE serum
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.04%
unknown, unknown
LEVOTHYROXINE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5.7 mg 1 times / day single, oral
Studied dose
Dose: 5.7 mg, 1 times / day
Route: oral
Route: single
Dose: 5.7 mg, 1 times / day
Sources:
healthy, 22 months
Health Status: healthy
Age Group: 22 months
Sex: M
Sources:
Other AEs: Hypertension, Tachycardia...
Other AEs:
Hypertension (grade 1)
Tachycardia (grade 1)
Sources:
18 mg 1 times / day single, oral
Studied dose
Dose: 18 mg, 1 times / day
Route: oral
Route: single
Dose: 18 mg, 1 times / day
Sources:
healthy, 30 months
Health Status: healthy
Age Group: 30 months
Sex: M
Sources:
Other AEs: Hyperthyroidism, Seizures...
Other AEs:
Hyperthyroidism
Seizures
Sources:
600 ug 1 times / day single, oral
Studied dose
Dose: 600 ug, 1 times / day
Route: oral
Route: single
Dose: 600 ug, 1 times / day
Sources:
healthy, mean age 35 years
Health Status: healthy
Age Group: mean age 35 years
Sex: M+F
Sources:
Disc. AE: Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Alanine aminotransferase increased (2.8%)
Sources:
50 ug steady, oral
Dose: 50 ug
Route: oral
Route: steady
Dose: 50 ug
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Atrial fibrillation, Palpitations...
Other AEs:
Atrial fibrillation (serious, 1 patient)
Palpitations (below serious, 3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypertension grade 1
5.7 mg 1 times / day single, oral
Studied dose
Dose: 5.7 mg, 1 times / day
Route: oral
Route: single
Dose: 5.7 mg, 1 times / day
Sources:
healthy, 22 months
Health Status: healthy
Age Group: 22 months
Sex: M
Sources:
Tachycardia grade 1
5.7 mg 1 times / day single, oral
Studied dose
Dose: 5.7 mg, 1 times / day
Route: oral
Route: single
Dose: 5.7 mg, 1 times / day
Sources:
healthy, 22 months
Health Status: healthy
Age Group: 22 months
Sex: M
Sources:
Hyperthyroidism
18 mg 1 times / day single, oral
Studied dose
Dose: 18 mg, 1 times / day
Route: oral
Route: single
Dose: 18 mg, 1 times / day
Sources:
healthy, 30 months
Health Status: healthy
Age Group: 30 months
Sex: M
Sources:
Seizures
18 mg 1 times / day single, oral
Studied dose
Dose: 18 mg, 1 times / day
Route: oral
Route: single
Dose: 18 mg, 1 times / day
Sources:
healthy, 30 months
Health Status: healthy
Age Group: 30 months
Sex: M
Sources:
Alanine aminotransferase increased 2.8%
Disc. AE
600 ug 1 times / day single, oral
Studied dose
Dose: 600 ug, 1 times / day
Route: oral
Route: single
Dose: 600 ug, 1 times / day
Sources:
healthy, mean age 35 years
Health Status: healthy
Age Group: mean age 35 years
Sex: M+F
Sources:
Palpitations below serious, 3 patients
50 ug steady, oral
Dose: 50 ug
Route: oral
Route: steady
Dose: 50 ug
Sources:
unhealthy
Health Status: unhealthy
Sources:
Atrial fibrillation serious, 1 patient
50 ug steady, oral
Dose: 50 ug
Route: oral
Route: steady
Dose: 50 ug
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Papillary carcinoma in thyroglossal duct cyst.
2001-12-19
[Treatment of euthyroid goiter in the elderly].
2001-12-01
Congenital hypothyroidism in a child with unsuspected familial dysalbuminemic hyperthyroxinemia caused by a mutation (R218H) in the human albumin gene.
2001-12
Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate.
2001-12
The role of thyroid hormone administration in potential organ donors.
2001-12
Coronary bypass surgery in patients with Sheehan's syndrome.
2001-12
Treatment of hypothyroidism.
2001-11-15
Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer.
2001-11
I take Synthroid for my underactive thyroid. What should I do if it is discontinued?
2001-11
Thyroid hormones modify susceptibility to lidocaine-kindling in rats.
2001-10-19
[Screening for thyroid disease. Occurrence of hypothyroidism and hyperthyroidism in patients admitted to a geriatric department].
2001-10-08
Abbott files NDA, will continue to distribute synthroid.
2001-10-01
Thyroid function test abnormalities in newly admitted psychiatric patients residing in an iodine-deficient area: patterns and clinical significance.
2001-10
The acute effect of calcium carbonate on the intestinal absorption of levothyroxine.
2001-10
Effect of 131 iodine therapy on the course of Graves' ophthalmopathy: a quantitative analysis of extraocular muscle volumes using orbital magnetic resonance imaging.
2001-10
Functional evidence for the presence of type II 5'-deiodinase in somatotropes and its adaptive role in hypothyroidism.
2001-10
Prevalence and characteristics of postpartum thyroid dysfunction in Tehran.
2001-10
[Euthyroid Graves' disease (problems of diagnosis and treatment)].
2001-09-25
[RTH syndrome--resistance to thyroid hormone syndrome].
2001-09-10
Acute aortic dissection associated with Sheehan's syndrome.
2001-09
Molecular cloning and sequence of Sparus aurata skeletal myosin light chains expressed in white muscle: developmental expression and thyroid regulation.
2001-09
Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease.
2001-09
Confusion over levothyroxine settled.
2001-08-15
The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line.
2001-08-10
Development of hypertensive status in NISAG rats reared by normotensive Wistar rats.
2001-08
Hyperthyroidism affects lipid metabolism in lactating and suckling rats.
2001-08
Effect of treatment of hypothyroidism on the plasma concentrations of neuroactive steroids and homocysteine.
2001-08
Managing hypothyroidism during pregnancy.
2001-08
Noncompliance with medical treatment: pseudomalabsorption of levothyroxine.
2001-08
Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status.
2001-08
Effects of thyroid hormone deficiency on electrocardiogram findings of congenitally hypothyroid neonates.
2001-08
Management practices among primary care physicians and thyroid specialists in the care of hypothyroid patients.
2001-08
Tall cell papillary thyroid carcinoma metastatic to femur: evidence for thyroid hormone synthesis within the femur.
2001-08
Thyroid hormones and thyroid antibodies in infertile males.
2001-08
Developmental landmarks in offspring of rats exposed singly and in combination to Aroclor 1016 and levothyroxine.
2001-08
[Morphological characteristics of placenta and hormonal balance in hyperthyroidism of pregnancy].
2001-07-17
What is going on with levothyroxine.
2001-07-09
Thyroid hormone deficiency determines predisposition to catalepsy in rats.
2001-07
Age-related changes of protein- and RNA-synthetic processes in experimental hyper- and hypothyroidism.
2001-07
Association between weight gain, blood parameters, and thyroid hormones and the development of ascites syndrome in broiler chickens.
2001-07
Stimulated healing of recalcitrant wounds by topical application of enriched cell culture medium: a clinical report.
2001-07
Use of soy protein supplement and resultant need for increased dose of levothyroxine.
2001-06-26
Five-year mortality in men and women with atrial fibrillation.
2001-06
The use of oral radiographic contrast agents in the management of hyperthyroidism.
2001-06
[The changes of PCBs and PCDFs as well as symptoms in Yusho patients for 30 years].
2001-05
A case of pulmonary metastatic thyroid cancer complicated with Graves' disease.
2001-04
Graves' disease presenting as elephantiasic pretibial myxedema and nodules of the hands.
2001-04
[Destabilizing effect of chicken selection using the functional adrenal reserves criteria].
2001-04
Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status.
2001
Improved antibody coating protocol using a second antibody antiserum. Application to total thyroxin immunoassay.
2001
Patents

Sample Use Guides

Usual Adult Dose for Hypothyroidism Average full replacement dose: 1.7 mcg/kg/day (e.g., 100 to 125 mcg/day for a 70 kg adult) orally Older patients may require less than 1 mcg/kg/day
Route of Administration: Oral
Addition of Levothyroxine at concentrations of 100-200 nM rescued rat cerebellar granule neurons (CGNs) from cell death in K5 in a dose-dependent manner. 200 nM T4 was also effective in maintaining the neurites of CGNs in K5.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:10:17 GMT 2025
Edited
by admin
on Mon Mar 31 18:10:17 GMT 2025
Record UNII
054I36CPMN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THYROXINE SODIUM SALT
MI  
Preferred Name English
LEVOTHYROXINE SODIUM ANHYDROUS
WHO-IP  
Common Name English
LEVOTHYROXINE SODIUM ANHYDROUS [WHO-IP]
Common Name English
THYROXINE SODIUM
Common Name English
Levothyroxine sodium [WHO-DD]
Common Name English
NSC-259940
Code English
LEVOTHYROXINUM NATRICUM ANHYDROUS [WHO-IP LATIN]
Common Name English
levothyroxine sodium [INN]
Common Name English
THYROXINE SODIUM SALT [MI]
Common Name English
L-TYROSINE, O-(4-HYDROXY-3,5-DIIODOPHENYL)-3,5-DIIODO-, MONOSODIUM SALT
Common Name English
Code System Code Type Description
MERCK INDEX
m10840
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID90883228
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
CAS
55-03-8
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-221-4
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
LEVOTHYROXINE SODIUM ANHYDROUS
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY Description: An almost white or slightly coloured powder, or a fine, slightly coloured, crystalline powder; odourless. Solubility: Very slightly soluble in water; slightly soluble in ethanol (~750 g/L) TS; practically insoluble in acetone R and ether R. It dissolves in solutions of alkali hydroxides. Category: Thyroid hormone.Storage: Levothyroxine sodium should be kept in a tightly closed container, protected from light.Additional information: Levothyroxine sodium may contain a variable quantity of water of crystallization; anhydrous levothyroxine sodium is hygroscopic. Definition: Levothyroxine sodium contains not less than 97.0% and not more than 101.0% of C15H10I4NNaO4, calculated with reference to the dried substance.
DAILYMED
054I36CPMN
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
NCI_THESAURUS
C175725
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
INN
453
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
FDA UNII
054I36CPMN
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
EVMPD
SUB122637
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
ALTERNATIVE
PUBCHEM
23666112
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
CHEBI
6446
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
NSC
259940
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
EVMPD
SUB08495MIG
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY
RXCUI
1372638
Created by admin on Mon Mar 31 18:10:17 GMT 2025 , Edited by admin on Mon Mar 31 18:10:17 GMT 2025
PRIMARY RxNorm
Related Record Type Details
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY